South Carolina Hemp Laws 2026: Total-THC Rules

South Carolina permits hemp farming and hemp products under the current 0.3% delta-9 federal definition, but federal hemp compliance does not by itself make Delta-8 or Delta-10 legal under state law. No licensed medical-cannabis dispensaries or adult-use retailers currently operate in the state, while a disputed, unimplemented 1980 therapeutic-research law creates an unresolved question about medical authorization on paper.

This article is general information about the law, published for educational purposes. It is not a substitute for the advice of an attorney. Laws change and vary by state — consult an attorney licensed in your jurisdiction about your specific situation. Information current as of August 2026.

South Carolina's Approach to Hemp and Cannabis

South Carolina permits hemp farming and consumption under the current federal definition of hemp: no more than 0.3% delta-9 THC on a dry-weight basis. The Congressional Research Service describes that current federal standard and the change scheduled for November 2026.

Meeting federal hemp standards does not make Delta-8 or Delta-10 products legal to sell in South Carolina today. In an October 4, 2021 official opinion, the South Carolina Attorney General concluded that the Hemp Farming Act exempts Delta-9 THC but not other THC isomers, leaving Delta-8 and Delta-10 within Schedule I. SLED and some local police have made arrests on that basis. No court has ruled on the issue, and the legislature has not enacted an explicit Delta-8 ban.

No licensed medical-cannabis dispensaries or adult-use retailers currently operate in South Carolina. The legal picture is nevertheless not simply “none.” Following an April 2026 federal rescheduling action, state Sen. Tom Davis and others argued that a dormant 1980 South Carolina law establishing a controlled-substances therapeutic-research program became active. The Department of Public Health has not implemented the program and no patient access exists. The dispute is described by the Charleston City Paper.

The Federal Regulations That Reshape South Carolina's Hemp Market

Section 781 of the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371), enacted as Public Law 119-37 on 2025-11-12, sets 2026-11-12 as the effective date for the federal hemp provisions. On that date, the federal standard applies a 0.3% total-THC test inclusive of THCA and delta-8, caps finished hemp products at 0.4 mg total THC per container, and excludes cannabinoids that are not naturally produced by the plant as well as naturally occurring cannabinoids synthesized outside the plant. On 2026-08-08, the Senate passed H.R. 6500 containing proposed one-month partial-delay language. That language was not enacted as part of P.L. 119-37. See the Congressional Research Service overview.

Section 781 schedules three related federal hemp-definition changes for 2026-11-12:

1. Total-THC standard: The federal hemp definition applies a 0.3% total-THC test inclusive of THCA and Delta-8 beginning 2026-11-12.

2. Finished-product cap: Finished hemp products are scheduled to contain no more than 0.4 mg total THC per container beginning 2026-11-12.

3. Cannabinoid exclusions: The federal hemp definition is scheduled to exclude cannabinoids not naturally produced by the plant and naturally occurring cannabinoids synthesized outside the plant.

Federal hemp impact: Beginning 2026-11-12, products that fail Section 781 will not qualify for sale as federally lawful hemp. That federal change does not itself decide South Carolina's separate, disputed medical-cannabis question.

What the Federal Change Does — and Does Not — Decide

The 2026-11-12 federal change governs the hemp channel. It does not erase the separate South Carolina legal dispute over the dormant 1980 therapeutic-research law. No dispensaries or licensed retailers operate today, but the dormant 1980 law creates an unresolved question about medical authorization on paper. See the report on that dispute.

Unique Considerations for South Carolina

Delta-8 already carries state-law risk. The 2021 Attorney General opinion treats it as Schedule I outside the hemp exemption, and some agencies enforce that position, even though no court has settled it.
No operating state-licensed retail alternative exists today. South Carolina has no operating medical dispensaries or adult-use retailers.
The medical-program question is unresolved. Some officials argue the dormant 1980 therapeutic-research law was activated in April 2026, but it has not been implemented and gives patients no present access.
The federal hemp channel narrows on 2026-11-12. Products that fail Section 781 of Public Law 119-37 will not qualify as federal hemp.

FAQs: South Carolina Hemp Laws & the 2026 Transition

Can I still buy Delta-8 products in South Carolina?

Buying Delta-8 already carries legal risk today, independent of the federal November 2026 change. The South Carolina Attorney General's 2021 opinion treats Delta-8 as a Schedule I controlled substance outside the Hemp Farming Act exemption. SLED and some local police have enforced that position, although no court has settled the question.

Does South Carolina have an operating medical or adult-use retail market?

No licensed medical-cannabis dispensaries or adult-use retailers currently operate in the state. A disputed 1980 therapeutic-research law may authorize medical marijuana on paper, according to some officials, but it has not been implemented and provides no patient access. See the report on the dispute.

Is the federal total-THC standard already in force?

No. Section 781's 0.3% total-THC test and 0.4 mg-per-container cap both take effect on 2026-11-12 under Public Law 119-37. See the Congressional Research Service overview.

Will the federal change end every legal route to intoxicating THC in South Carolina?

It will narrow the federal hemp channel: after 2026-11-12, hemp products exceeding 0.4 mg total THC per container will not qualify as federally lawful hemp. It does not settle the separate, disputed South Carolina medical-cannabis question described above.